|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 64
Zeitschriftenartikel
Haubner, S.; Perna, F.; Koehnke, T.; Schmidt, C.; Berman, S.; Augsberger, C.; Schnorfeil, F. M.; Krupka, C.; Lichtenegger, F. S.; Liu, X.; Kerbs, P.; Schneider, S.; Metzeler, K. H.; Spiekermann, K.; Hiddemann, W.; Greif, P. A.; Herold, T.; Sadelain, M. und Subklewe, M.
(2019):
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
In: Leukemia, Bd. 33, Nr. 1: S. 64-74
Beck, D.; Thoms, J. A. I.; Palu, C.; Herold, T.; Shah, A.; Olivier, J.; Boelen, L.; Huang, Y.; Chacon, D.; Brown, A.; Babic, M.; Hahn, C.; Perugini, M.; Zhou, X.; Huntly, B. J.; Schwarzer, A.; Klusmann, J-H; Berdel, W. E.; Wörmann, B.; Büchner, T.; Hiddemann, W.; Bohlander, S. K.; To, L. B.; Scott, H. S.; Lewis, I. D.; D'Andrea, R. J.; Wong, J. W. H. und Pimanda, J. E.
(2018):
A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
In: Leukemia, Bd. 32, Nr. 2: S. 263-272
Reiter, K.; Polzer, H.; Krupka, C.; Maiser, A.; Vick, B.; Rothenberg-Thurley, M.; Metzeler, K. H.; Doerfel, D.; Salih, H. R.; Jung, G.; Noessner, E.; Jeremias, I.; Hiddemann, W.; Leonhardt, H.; Spiekermann, K.; Subklewe, M. und Greif, P. A.
(2018):
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
In: Leukemia, Bd. 32, Nr. 2: S. 313-322
Angenendt, L.; Bormann, E.; Braun, L.; Mikesch, J.-H.; Herold, T.; Metzeler, K.; Bohlander, S.; Görlich, D.; Arteaga, M. F.; Wörmann, B. J.; Lenz, G.; Müller-Tidow, C.; Hiddemann, W.; Spiekermann, K.; Krug, U.; Sauerland, M. C.; Berdel, W. E. und Schliemann, C.
(2017):
Calcitonin Receptor-like (CALCRL) expression predicts poor survival in acute myeloid leukemia.
In: Oncology Research and Treatment, Bd. 40: S. 27
Heckl, B. C.; Carlet, M.; Grunert, M.; Vick, B.; Roolf, C.; Junghanss, C.; Spiekermann, K.; Hiddemann, W. und Jeremias, I.
(2017):
Adult primary acute leukemia samples with chromosomal translocations grow well in immunodeficient mice, but are difficult to transduce with lentiviruses.
In: Haematologica, Bd. 102: S. 656-657
Prassek, V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W. E.; Wörmann, B.; Braess, J.; Hiddemann, W.; Spiekermann, K. und Metzeler, K. H.
(2017):
AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients?
In: Haematologica, Bd. 102: S. 209-210
Hiddemann, W.; Barbui, A. M.; Albendea, M. A. Canales; Cannell, P. K.; Collins, G. P.; Dürig, J.; Forstpointner, R.; Herold, M.; Hertzberg, M.; Klanova, M.; Radford, J. A.; Tobinai, K.; Burciu, A.; Fingerle-Rowson, G. R.; Nielsen, T.; Wolbers, M. und Marcus, R. E.
(2017):
Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen.
In: Haematologica, Bd. 102: S. 314
Pott, C.; Delfau, M.; Macintyre, E.; Ribrag, V.; Klapper, W.; Unterhalt, M.; Kneba, M.; Hiddemann, W.; Hermine, O.; Kluin-Nelemans, H.; Dreyling, M. und Hoster, E.
(2017):
Implications of deep molecular response after induction and in maintenance treatment in elderly patients with mantle cell lymphoma: updated results of the randomized EU-MCL elderly trial.
In: Oncology Research and Treatment, Bd. 40: S. 13
Fischer, L.; Mayer, A.; Irger, M.; Freysoldt, B.; Zimmermann, Y.; Hutter, G.; Hiddemann, W. und Dreyling, M.
(2017):
CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIB.
In: Haematologica, Bd. 102: S. 575
Jäger, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Winkler, E. und Heussner, P.
(2017):
Patients' preferences concerning their information needs and their preferred role in participation in end-of-life decision-making (EPAL-Study).
In: Oncology Research and Treatment, Bd. 40: S. 281-282
Fraccaroli, A.; Prevalsek, D.; Häbe, S.; Schulz, C.; Roiss, M.; Bücklein, V.; Lippl, S.; Herold, T.; Stemmler, H.-J.; Spiekermann, K.; Ledderose, G.; Hiddemann, W. und Tischer, J.
(2017):
HLA haploidentical allografting using post transplantation cyclophosphamide in high-risk and advanced MDS and AML patients aged over 50 years: feasibility and outcome.
In: Oncology Research and Treatment, Bd. 40: S. 102
Herold, M.; Hoster, E.; Unterhalt, M.; Hänel, M.; Prange-Krex, G.; Forstpointner, R.; Florschütz, A.; Gräven, U.; Frickhofen, N.; Wulf, G.; Lengfelder, E.; Lerchenmüller, C.; Schlag, R.; Dierlamm, J.; Fischer von Weikersthal, L.; Ahmed, A.; Harich, H.-D.; Rosenwald, A.; Klapper, W.; Dreyling, M. und Hiddemann, W.
(2017):
Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomized trial of GLSG and OSHO.
In: Oncology Research and Treatment, Bd. 40: S. 74
Bücklein, V. L.; Krause, S.; Ölschlägel, U.; Köhnke, T.; Schnorfeil, F.; Völkl, S.; Rieger, M. A.; Berg, T.; Hoffmann, J.; Brendel, C.; Hiddemann, W.; Subklewe, M. und Bonin, M. von
(2017):
Defining minimal residual disease by flow cytometry in acute myeloid leukemia: the HARMONIZE initiative.
In: Oncology Research and Treatment, Bd. 40: S. 43
Prassek, V. V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W.; Wörmann, B.; Bräss, J.; Spiekermann, K.; Hiddemann, W. und Metzeler, K.
(2017):
AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients?
In: Oncology Research and Treatment, Bd. 40: S. 29
Bürke, M.; Hasenfuß, G.; Hiddemann, W. und Sieber, C. C.
(2017):
Internistische Notfälle an der Schnittstelle von ambulant und stationär.
In: Internist, Bd. 58, Nr. 9: S. 881-882
Vick, B.; Holdt, L. M.; Hiddemann, W.; Spiekermann, K. und Jeremias, I.
(2017):
Modeling AML Standard Induction Chemotherapy in the PDX Mouse Model.
In: Annals of Hematology, Bd. 96:
S68-S68
Heckl, B.; Carlet, M.; Grunert, M.; Vick, B.; Roolf, C.; Junghanss, C.; Spiekermann, K.; Hiddemann, W. und Jeremias, I.
(2017):
Primary Adult Acute Lymphoblastic Leukemic Cells Reliably Engraft and Grow in Immunodeficient Mice.
In: Annals of Hematology, Bd. 96:
S71-S72
Vosberg, S.; Hartmann, L.; Metzeler, K. H.; Schumacher, D.; Pastore, F.; Bräundl, K.; Zellmeier, E.; Ksienzyk, B.; Konstandin, N. P.; Schneider, S.; Graf, A.; Krebs, S.; Blum, H.; Neumann, M.; Baldus, C. D.; Bohlander, S. K.; Wolf, S.; Hiddemann, W.; Spiekermann, K. und Greif, P. A.
(2017):
Evolutionary Patterns of Cytogenetically Normal Acute Myeloid Leukemia Correlate with Time to Relapse.
In: Annals of Hematology, Bd. 96:
S55-S55
Konstandin, N. P.; Pastore, F.; Dufour, A.; Metzeler, K. H.; Rothenberg-Thurley, M.; Herold, T.; Schneider, S.; Ksienzyk, B.; Tschuri, S.; Berdel, W. E.; Wörmann, B. J.; Sauerland, C.; Bräss, J.; Stefan, B. K.; Hiddemann, W. und Spiekermann, K.
(2017):
Genetic Characterization of a Large Group of CEBPA Mutated AML Patients and the Effect of TET2 and GATA2 Mutations on Outcome.
In: Haematologica, Bd. 102: S. 363-364
Marcus, R.; Davies, A.; Ando, K.; Klapper, W.; Opat, S.; Owen, C.; Phillips, E.; Sangha, R.; Schlag, R.; Seymour, J. F.; Townsend, W.; Trněný, M.; Wenger, M.; Fingerle-Rowson, G.; Rufibach, K.; Moore, T.; Herold, M. und Hiddemann, W.
(2017):
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
In: New England Journal of Medicine, Bd. 377, Nr. 14: S. 1331-1344
Trotman, J.; Barrington, S.; Belada, D.; Meignan, M.; MacEwan, R.; Owen, C.; Ptacnik, V.; Rosta, A.; Fingerle-Rowson, G.; Mattiello, F.; Nielsen, T.; Sahin, D.; Hiddemann, W.; Marcus, R. und Davies, A.
(2017):
Comparison Of Contrast-Enhanced Ct-Based Response With Pet Assessment After First-Line Therapy For Follicular Lymphoma In The Phase Iii Gallium Study.
In: Haematologica, Bd. 102: S. 313-314
Pachzelt, L.; Krupka, C.; Kischel, R.; Kufer, P.; Köhnke, T.; Polzer, H.; Spiekermann, K.; Hiddemann, W. und Subklewe, M.
(2017):
Costimulation Increases Intracellular Signalling In Bite (R) Antibody Construct Mediated T-Cell Activation.
In: Haematologica, Bd. 102: S. 361
Costanzi, M.; Krupka, C.; Kischel, R.; Kufer, P.; Köhnke, T.; Spiekermann, K.; Hiddemann, W. und Subklewe, M.
(2017):
Secretion Of Soluble Factors By AML Cells Influence CD33/CD3 BITE (R) Antibody Mediated Cytotoxicity And T-Cell Proliferation.
In: Haematologica, Bd. 102: S. 357-358
Bamopoulos, S. A.; Batcha, A. M. N.; Jurinovic, V.; Metzeler, K. H.; Thurley, M. Rothenberg; Ksienzyk, B.; Hartmann, L.; Greif, P. A.; Phillippou-Massier, J.; Krebs, S.; Blum, H.; Amler, S.; Schneider, S.; Konstandin, N.; Sauerland, M. C.; Berdel, W. E.; Woermann, B. J.; Bohlander, S. K.; Braess, J.; Hiddemann, W.; Mansmann, Ulrich; Spiekermann, K. und Herold, T.
(2017):
Characterization of Spliceosome Mutations in Patients with Acute Myeloid Leukemia.
In: Annals of Hematology, Bd. 96:
S60-S60
Janich, S.; Hartmann, L.; Vosberg, S.; Matte, R.; Polzer, H.; Leonhard, H.; Greif, P.; Hiddemann, W. und Spiekermann, K.
(2017):
Functional Characterization of the H3K27 Demethylase KDM6A in Acute Myeloid Leukemia.
In: Annals of Hematology, Bd. 96:
S57-S58
Köhnke, Thomas; Rechkemmer, S.; Buecklein, V.; Hiddemann, W.; Spiekermann, K. und Subklewe, Marion
(2017):
Early Detection and Alternative Gating Strategies in Flow MRD.
In: Annals of Hematology, Bd. 96:
S26-S28
Krupka, C.; Lindl, B.; Kischel, R.; Kufer, P.; Lichtenegger, F. S.; Köhnke, T.; Augsberger, C.; Altmann, T.; Spiekermann, K.; Hiddemann, W. und Subklewe, Marion
(2017):
Influence of Cytoreductive and Immunmodulatory Drugs on Bispecific T-Cell Engager-Based Approaches in AML.
In: Annals of Hematology, Bd. 96:
S81-S82
Polzer, H.; Hiddemann, W. und Spiekermann, K.
(2017):
Functional Characterization of The Impact of FLT3 Receptor Domains on Cell Signaling.
In: Annals of Hematology, Bd. 96:
S60-S61
Prassek, V. V.; Rothenberg-Thurley, M.; Herold, T.; Amler, S.; Sauerland, M. C.; Goerlich, D.; Janke, H.; Schneider, S.; Subklewe, Marion; Krug, U.; Faldum, A.; Berdel, W. E.; Woermann, B.; Buechner, T.; Braess, J.; Hiddemann, W.; Spiekermann, K. und Metzeler, K. H.
(2017):
AML Patients Aged >= 75 Years Enrolled into AMLCG Trials: Do Gene Mutations Impact Clinical Outcome in Very Old, Intensively Treated Patients?
In: Annals of Hematology, Bd. 96:
S63-S63
Reiter, K.; Hubmann, M.; Harin, E.; Vosberg, S.; Braeundl, K.; Ksienzyk, B.; Schneider, S.; Dufour, A.; Zellmeier, E.; Bohlander, S. K.; Sauerland, C.; Berdel, W. E.; Woermann, B.; Buechner, T.; Braess, J.; Hiddemann, W.; Spiekermann, K. und Greif, A.
(2017):
Comparison of FLT3-ITD Detection of High-Throughput Amplicon Sequencing to Routine Diagnostics - A Retrospective Analysis of AMLCG Study Patients.
In: Annals of Hematology, Bd. 96:
S62-S62
Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Batcha, A. M.; Ksienzyk, B.; Zellmeier, E.; Mansmann, Ulrich; Subklewe, Marion; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, Klaus H.
(2017):
Persistence of Driver Mutations during Complete Remission Associates with Shorter Survival and Contributes to the Inferior Outcomes of Elderly Patients with Acute Myeloid Leukemia.
In: Annals of Hematology, Bd. 96:
S31-S32
Tischer, Johanna; Zoellner, A. K.; Prevalsek, D.; Köhnke, T.; Fritsch, S.; Schulz, C.; Lippl, S.; Kruger, S.; Haebe, S.; Berking, S.; Fraccaroli, A.; Ledderose, G.; Spiekermann, K.; Bug, G.; Hausmann, A.; Schmid, C.; Albert, M. und Hiddemann, W.
(2017):
Haploidentical Stem Cell Transplantation in ALL.
In: Annals of Hematology, Bd. 96:
S39-S40
Herold, Tobias; Jurinovic, V.; Metzeler, K. H.; Batcha, A. M. N.; Bamopoulos, S. A.; Rothenberg-Thurley, M.; Ksienzyk, B.; Hartmann, L.; Greif, P. A.; Phillippou-Massier, J.; Krebs, S.; Blum, H.; Amler, S.; Schneider, S.; Konstandin, N.; Sauerland, M. C.; Berdel, W. E.; Wörmann, B. J.; Subklewe, M.; Fiegl, M.; Bohlander, S. K.; Braess, J.; Hiddemann, W.; Mansmann, Ulrich und Spiekermann, K.
(2017):
Prediction of Primary Refractory Acute Myeloid Leukemia.
In: Annals of Hematology, Bd. 96:
S25-S25
Pohlen, M.; Braess, J.; Thudium, J.; Schmid, C.; Kochanek, M.; Kreuzer, K.-A.; Görlich, D.; Gerth, U.; Rhode, C.; Müller-Tidow, C.; Stelljes, M.; Büchner, T.; Schlimok, G.; Hallek, M.; Waltenberger, J.; Hiddemann, W.; Berdel, W. E.; Heilmeier, B. und Krug, U.
(2016):
Patients with acute myeloid leukemia admitted to intensive care units: Scores predicting outcome and post-ICU survival.
In: Oncology Research and Treatment, Bd. 39: S. 51
Mehlis, K.; Jaeger, E.; Laryionava, K.; Mumm, F.; Hiddemann, W.; Heussner, P. und Winkler, E. C.
(2016):
Importance of a good patient-communication in situations of treatment limitation - results from the EPAL-Study (Ethics Policy for Advanced Care Planning and Limiting Treatment).
In: Oncology Research and Treatment, Bd. 39: S. 302-303
Jaeger, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Winkler, E. C. und Heussner, P.
(2016):
Patients' preferences concerning quality and quantity of life. Results from the EPAL-Study (Ethics Policy for Advanced Care Planning and Limiting Treatment).
In: Oncology Research and Treatment, Bd. 39: S. 303
Mehlis, K.; Jaeger, E.; Laryionava, K.; Mumm, F.; Hiddemann, W.; Heussner, P. und Winkler, E. C.
(2016):
Patients' information needs and involvement in decisions to limit treatment in the EPAL-Study (Ethics policy for advanced care planning and limiting treatment).
In: Oncology Research and Treatment, Bd. 39: S. 303
Krupka, C.; Kufer, P.; Kischel, R.; Zugmaier, G.; Lichtenegger, F. S.; Köhnke, T.; Vick, B.; Jeremias, I.; Metzeler, K. H.; Altmann, T.; Schneider, S.; Fiegl, M.; Spiekermann, K.; Bauerle, P. A.; Hiddemann, W.; Riethmüller, G. und Subklewe, M.
(2016):
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
In: Leukemia, Bd. 30, Nr. 2: S. 484-491
Ferrero, S.; Pastore, A.; Scholz, C. W.; Forstpointner, R.; Pezzutto, A.; Bergmann, L.; Trümper, L.; Finke, J.; Keller, U.; Ghione, P.; Passera, R.; Hiddemann, W.; Weigert, O.; Unterhalt, M. und Dreyling, M.
(2016):
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
In: Leukemia, Bd. 30, Nr. 4: S. 984-987
Berdel, W. E.; Hehlmann, R.; Hoelzer, D. und Hiddemann, W.
(2016):
Prof. Thomas Buchner (22 September 1934-5 August 2016) OBITUARY.
In: Leukemia, Bd. 30, Nr. 11: S. 2131-2132
Krug, U.; Berdel, W. E.; Gale, R. P.; Haferlach, C.; Schnittger, S.; Müller-Tidow, C.; Braess, J.; Spiekermann, K.; Staib, P.; Beelen, D.; Serve, H.; Schliemann, C.; Stelljes, M.; Balleisen, L.; Maschmeyer, G.; Grüneisen, A.; Eimermacher, H.; Giagounidis, A.; Rasche, H.; Hehlmann, R.; Lengfelder, E.; Thiel, E.; Reichle, A.; Aul, C.; Ludwig, W.-D.; Kern, W.; Haferlach, T.; Köpcke, W.; Görlich, D.; Sauerland, M. C.; Heinecke, A.; Wörmann, B. J.; Hiddemann, W. und Büchner, T.
(2016):
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
In: Leukemia, Bd. 30, Nr. 6: S. 1230-1236
Büchner, T.; Krug, U. O.; Gale, R. Peter; Heinecke, A.; Sauerland, M. C.; Haferlach, C.; Schnittger, S.; Haferlach, T.; Müller-Tidow, C.; Stelljes, M.; Mesters, R. M.; Serve, H. L.; Braess, J.; Spiekermann, K.; Staib, P.; Grüneisen, A.; Reichle, A.; Balleisen, L.; Eimermacher, H.; Giagounidis, A.; Rasche, H.; Lengfelder, E.; Görlich, D.; Faldum, A.; Köpcke, W.; Hehlmann, R.; Wörmann, B. J.; Berdel, W. E. und Hiddemann, W.
(2016):
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
In: Leukemia, Bd. 30, Nr. 8: S. 1781-1784
Haebe, S.; Totok, G.; Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zöllner, A.-K.; Köhnke, T.; Schulz, C.; Ledderose, G.; Hausmann, A.; Hiddemann, W. und Tischer, J.
(2016):
HLA-haploidentical transplantation using T-cell-replete grafts and high-dose cyclophosphamide post-transplantation in the treatment of multiple myeloma: a single center experience.
In: Bone Marrow Transplantation, Bd. 51:
S356-S357
Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zoellner, A.-K.; Koehnke, T.; Buecklein, V. L.; Mumm, F.; Haebe, S.; Witkowski, L.; Ledderose, G.; Stemmler, H.-J.; Spiekermann, K.; Hiddemann, W.; Hausmann, A. und Tischer, J.
(2016):
Sequential therapy in the setting of HLA-haploidentical transplantation utilizing T-cell-replete grafts and post-transplantation high-dose cyclophosphamide in the treatment of relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome.
In: Bone Marrow Transplantation, Bd. 51:
S29-S30
Hartmann, L.; Dutta, S.; Opatz, S.; Vosberg, S.; Reiter, K.; Leubolt, G.; Metzeler, K. H.; Herold, T.; Bamopoulos, S. A.; Bräundl, K.; Zellmeier, E.; Ksienzyk, B.; Konstandin, N. P.; Schneider, S.; Hopfner, K. P.; Graf, A.; Krebs, S.; Blum, H.; Middeke, J. M.; Stölzel, F.; Thiede, C.; Wolf, S.; Bohlander, S. K.; Preiss, C.; Chen-Wichmann, L.; Wichmann, C.; Sauerland, M. C.; Büchner, T.; Berdel, W. E.; Wörmann, B. J.; Braess, J.; Hiddemann, W.; Spiekermann, K. und Greif, P. A.
(2016):
Frequent recurring mutations disrupt the anti-proliferative function of ZBTB7A in acute myeloid leukemia with t(8;21) translocation.
In: Haematologica, Bd. 101: S. 11
Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Batcha, A. M. Nazeer; Bräundl, K.; Ksienzyk, B.; Zellmeier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, K. H.
(2016):
Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia.
In: Haematologica, Bd. 101: S. 23
Beck, D.; Thoms, J.; Palu, C.; Herold, T.; Shah, A.; Olivier, J.; Boelen, L.; Huang, Y.; Chacon, D.; Brown, A.; Babic, M.; Hahn, C.; Perugini, M.; Zhou, X.; Huntly, B.; Berdel, W.; Wörmann, B.; Büchner, T.; Hiddemann, W.; Bohlander, S.; Scott, H.; Lewis, I.; D'Andrea, R.; Wong, J. und Pimanda, J.
(2016):
Integrative analysis of lincRNA expression in 922 acute myeloid leukemia patients reveals multiple prognostic gene signatures.
In: Haematologica, Bd. 101: S. 208-209
Hutter, G.; Zimmermann, Y.; Zoellner, A.; Irrgang, P.; Arnd, J.; Hiddemann, W. und Dreyling, M.
(2016):
Mode of action of different PI3K-inhibitors in mantle cell lymphoma.
In: Haematologica, Bd. 101: S. 271
Winkler, E.; Mehlis, K.; Jaeger, E.; Laryionava, K.; Hiddemann, W. und Heussner, P.
(2016):
The EPAL-project (Ethics policy for advanced care planning and limiting treatment).
In: Oncology Research and Treatment, Bd. 39: S. 33-34
Feder, K.; Edmaier, K.; Eshraghi, P.; Vegi, N.; Mulaw, M.; Ihme, S.; Spiekermann, K.; Metzeler, K.; Hiddemann, W.; Döhner, K.; Döhner, H.; Feuring-Buske, M. und Buske, C.
(2016):
The Lef1 isoform, lacking the β-catenin binding domain, is not acting as a dominant negative Lef1 variant, but is a hematopoietic active protein with unique DNA binding properties.
In: Oncology Research and Treatment, Bd. 39: S. 46
Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zoellner, A.-K.; Köhnke, T.; Engel, N.; Bücklein, V. L.; Schulz, C.; Mumm, F.; Berking, S.; Ledderose, G.; Stemmler, H.-J.; Spiekermann, K.; Hiddemann, W.; Hausmann, A. und Tischer, J.
(2016):
Results of sequential therapy in the setting of unmanipulated HLA-haploidentical transplantation utilizing post-transplantation high-dose cyclophosphamide in the treatment of high-risk AML and MDS.
In: Oncology Research and Treatment, Bd. 39: S. 77-78
Krupka, C.; Lindl, B.; Platzer, J.; Brauneck, F.; Kischel, R.; Kufer, P.; Lichtenegger, F. S.; Köhnke, T.; Rothe, M.; Deiser, K.; Augsberger, C.; Altmann, T.; Spiekermann, K.; Hiddemann, W. und Subklewe, M.
(2016):
Influence of cytoreductive and immunmodulatory drugs on antibody-based approaches in AML.
In: Oncology Research and Treatment, Bd. 39: S. 84-85
Rothenberg-Thurley, M.; Amler, S.; Görlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Nazeer Batcha, A. M.; Bräundl, K.; Ksienzyk, B.; Zellmaier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, K. H.
(2016):
Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia.
In: Oncology Research and Treatment, Bd. 39: S. 110-111
Herzog, A.; Knecht, H.; Herrmann, D.; Unterhalt, M.; Hiddemann, W.; Kneba, M.; Brueggemann, M.; Hoster, E. und Pott, C.
(2016):
IgH-based Next -Generation Sequencing for MRD detection in follicular lymphoma.
In: Oncology Research and Treatment, Bd. 39: S. 120
Lichtenegger, F. S.; Deiser, K.; Rothe, M.; Krupka, C.; Schnorfeil, F. M.; Augsberger, C.; Köhnke, T.; Bücklein, V; Altmann, T.; Moosmann, A.; Brüggemann, M.; Heemskerk, M. H. M.; Wagner, B.; Hiddemann, W.; Bigalke, I; Kvalheim, G. und Subklewe, M.
(2016):
Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I/II trial and ex vivo enhancement by checkpoint blockade.
In: Oncology Research and Treatment, Bd. 39: S. 135
Kvint, R.; Zimmermann, Y.; Hutter, G.; Hiddemann, W. und Dreyling, M.
(2016):
High efficiency of the pan-PI3K/mTOR inhibitor, PQR-309, in MCL.
In: Oncology Research and Treatment, Bd. 39: S. 153-154
Hutter, G.; Zimmermann, Y.; Bamopoulos, S. A.; Irger, M.; Hiddemann, W. und Dreyling, M.
(2016):
Synergistic effect of inhibition of multiple PI3K-isoforms due to the differential mode of action of single PI3K-isoform inhibitors in mantle cell lymphoma.
In: Oncology Research and Treatment, Bd. 39: S. 154
Laryionava, K.; Mehlis, K.; Hiddemann, W.; Heußner, P. und Winkler, E. C.
(2016):
"Rather one more chemo than one less ..." Young adult's patients and chemotherapy in advanced cancer. A study of oncologists' views.
In: Oncology Research and Treatment, Bd. 39: S. 230
Jaeger, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Winkler, E. C. und Heußner, P.
(2016):
Development and Validity of a Checklist Assessing the Risk of Bias of Randomized Trials, Observational Studies and Systematic Reviews Analyzing Drug Adverse Events.
In: Oncology Research and Treatment, Bd. 39: S. 241
Hiddemann, W.; Hoster, E.; Schmidt, C. und Unterhalt, M.
(2016):
Has the time come for chemotherapy-free therapy of follicular lymphoma?
In: Oncology Research and Treatment, Bd. 39: S. 301-302
Jaeger, E.; Winkler, E.; Mehlis, K.; Mumm, F.; Laryionava, K.; Hiddemann, W. und Heußner, P.
(2016):
End-of-Life decision-making in patients with advanced cancer - an ethics policy for advanced care planning and limiting treatment (EPAL).
In: Oncology Research and Treatment, Bd. 39: S. 31-32
Mehlis, K.; Jaeger, E.; Mumm, F.; Laryionava, K.; Hiddemann, W.; Heußner, P. und Winkler, E. C.
(2016):
Patient information needs and treatment goals in the EPAL-Study (Ethics policy for advanced care planning and limiting treatment).
In: Oncology Research and Treatment, Bd. 39: S. 31
Ponnusamy, K.; Kohrs, N.; Ptasinska, A.; Assi, S. A.; Herold, T.; Hiddemann, W.; Lausen, J.; Bonifer, C.; Henschler, R. und Wichmann, C.
(2015):
RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1.
In: Oncogenesis, Bd. 4, e146
[PDF, 1MB]
Hehlmann, R.; Berger, U.; Aul, C.; Büchner, Th; Dohner, H.; Ehninger, G.; Ganser, A.; Gökbuget, Nicola; Hoelzer, D.; Überla, Karl; Gassmann, W.; Ludwig, W. D.; Rieder, H.; Kneba, M.; Hochhaus, A.; Reiter, A.; Hiddemann, W.; Ottmann, O. G.; Germing, U.; Adelhard, K.; Dugas, M.; Dirschedl, P.; Messerer, D.; Böhme, A.; Harrison-Neu, E.; Griesshammer, M.; Kienast, J.; Kolb, H. J.; Ho, A. D.; Hallek, M.; Neubauer, A.; Schlegelberger, B.; Niederwieser, D.; Heil, G.; Müller, T. und Hasford, Joerg
(2004):
The German competence network 'Acute and chronic leukemias'.
In: Leukemia, Bd. 18, Nr. 4: S. 665-669